HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of Alzheimer’s disease (AD), including for patients at risk for AD because of vascular-related risk factors or disease. An important new study has found that people who take statin drugs were about half as likely to develop dementia or clinically significant cognitive impairment as those who did not use statins (Neurology July 29, 2008; 71:344-355). Unlike earlier retrospective epidemiological studies, the University of Michigan study was specifically designed to include a prospective examination of the preventive effect of statins on the risk of dementia or cognitive impairment.
